SYSTEMATIC REVIEW article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1566604
This article is part of the Research TopicInnovative Strategies for Overcoming Resistance in Tumor Angiogenesis TherapiesView all 3 articles
Efficacy and safety analyses of bevacizumab in neoadjuvant chemotherapy for ovarian cancer: a systematic review and meta-analysis
Provisionally accepted
- Department of Obstetrics and Gynecology, Dalian Municipal Central Hospital, Dalian, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To assess the efficacy and safety of bevacizumab in neoadjuvant chemotherapy for ovarian cancer through systematic evaluation and meta-analysis.Methods: Online databases, such as PubMed, Embase, and the Cochrane Library, were searched for relevant articles on the treatment of ovarian cancer patients with interval debulking surgery after neoadjuvant chemotherapy in combination with the bevacizumab regimen using the keywords "Ovarian Neoplasms," "Bevacizumab," "Monoclonal antibodies against vascular endothelial growth factor," "Avastin," and "Neoadjuvant Therapy." A meta-analysis of the screened literature, which included randomized controlled trials and cohort studies, was then performed using Stata 15.0 software.The meta-analysis included five eligible papers. The test group consisted of 160 patients who received paclitaxel + carboplatin + bevacizumab prior chemotherapy (TCB), whereas the control group consisted 211 patients who received paclitaxel + carboplatin (TC). The results indicate that there was no significant difference between the two groups in terms of the rate of optimal cytoreduction(RR=1.124,95% CI: 0.947-1.335,P =0.182 ;Heterogeneity:I 2 = 40.3%,p= 0.152) and progression-free survival (PFS) (HR=0.74, 95% CI: 0.48-1.14 ,p = 0.173;Heterogeneity:I 2 = 86%, p = 0.007). Neoadjuvant chemotherapy with bevacizumab did not increase the incidence of adverse events in chemotherapy(RR=0.88,95% CI: 0.713-1.088,p = 0.238;Heterogeneity:I 2 = 49.5%, p = 0.095).The rate of postoperative complications in the TCB group was comparable to that in the TC group(RR=0.955,95% CI:0.672-1.359 ,p = 0.799;Heterogeneity:I 2 = 6.8% ,p = 0.368).The use of bevacizumab in neoadjuvant chemotherapy for advanced ovarian cancer was safe and feasible but did not significantly improve the satisfactory tumor reduction rate of interval debulking surgery and had no effect on the prolongation of postoperative PFS. Hence, the use of bevacizumab in preemptive chemotherapy for ovarian cancer should be carefully considered.
Keywords: Ovarian Neoplasms, bevacizumab, monoclonal antibodies against vascular endothelial growth factor, Avastin, Neoadjuvant chemotherapy
Received: 22 Feb 2025; Accepted: 23 May 2025.
Copyright: © 2025 Wang, Wang, Wang, Yuan, Yu and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yongai Yu, Department of Obstetrics and Gynecology, Dalian Municipal Central Hospital, Dalian, China
Daju Liu, Department of Obstetrics and Gynecology, Dalian Municipal Central Hospital, Dalian, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.